Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eExos-miR-135
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
eExos-miR-135 is an engineered exosome-based gene delivery system designed for the treatment of glioblastoma. These exosomes (eExos) are modified to express retroviral Gag and VSVg proteins, which enhances the packaging and delivery efficiency of genetic cargo. In this specific formulation, the eExos deliver a plasmid encoding miR-135 (specifically miR-135-a-2), a microRNA identified through high-throughput screening as a potent anti-glioma agent. The mechanism involves the delivery of miR-135 into glioma stem cells (GSCs), where it acts to inhibit cell proliferation and tumor growth. Research conducted by MD Anderson Cancer Center and Baylor College of Medicine has demonstrated that these engineered exosomes can effectively cross biological barriers and deliver therapeutic miRs in both in vitro and in vivo glioblastoma models.
- Other names
- eExos-miR-135-a-2eExos-miR135-a-2eExos-miR 135-a-2engineered exosomes containing miR-135
02
Targets
FOXO1 (Forkhead box protein O1)LATS2 (Large tumor suppressor kinase 2)miR-135 (MicroRNA 135)
Beyond the preview
Go deeper on eExos-miR-135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eExos-miR-135.